AIRS Medical, a Seoul, South Korea-based healthcare startup, raised $20M in Series B funding.
The round was led by Q Capital Partners with participation from Hanwha Life and Klim Ventures.
The company intends to use the funds to accelerate growth and expand operations.
Led by CEO Hye-seong Lee, AIRS Medical uses digitalized, AI-based diagnostic tests and robotics technologies to provide a better clinical experience for both patients and healthcare providers. The startup developed and commercialized its technology, called SwiftMR™, an AI-powered MRI reconstruction software platform that enhances MR images acquired under various conditions, contributing to a higher level of data accuracy and a better patient experience. In 2021, the software was approved by both the Korea Ministry of Food and Drug Safety (MFDS) and the US FDA. Since its official commercial launch in Korea in the fourth quarter of 2021, SwiftMR™ has been used for an average of 30,000 monthly MRI exams and a grand total of more than 130,000 MRI exams. Following the implementation of the software’s business model in the domestic market and with the support of Born2Global and the KOSME-MATTER US Market Adoption Program, AIRS Medical is now introducing its software in other parts of the world including the United States, Europe, Southeast Asia, and South America.
In March 2022, AIRS Medical acquired artiQ, an AI- and robotics-based startup that shared AIRS Medical’s vision of a world without any sickness. Through the acquisition, AIRS Medical added in-vitro diagnostics to its technology portfolio, which also includes venipuncture automation. Moving forward, the company aims to use its technology and clinical expertise to introduce consecutive diagnostic test solutions that innovate the cost structure of the medical industry.
The company is a member of the Born2Global Centre.
FinSMEs
19/08/2022